Documentos relacionados

1. Risk models in myelofibrosis-the past, present, and future.
2. Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM.
3. Evidence creation for myelofibrosis: Challenges and opportunities.
4. Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives.
5. Myelofibrosis.
6. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.
7. Clonal Evolution after Allogeneic Hematopoietic Stem Cell Transplantation: The Case of Myelofibrosis.
8. Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.
9. [Allogeneic hematopoietic cell transplantation for myelofibrosis: current status and future challenges].
10. Defining disease modification in myelofibrosis in the era of targeted therapy.